PILOT STUDIES

试点研究

• 批准号: 6409930
• 负责人: VICTOR M HESSELBROCK
• 金额: $ 18.46万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-12-01 至 2001-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6409930
• 关键词: GABA receptor; adolescence (12-20); alcoholism /alcohol abuse; alcoholism /alcohol abuse chemotherapy; animal genetic material tag; antisense nucleic acid; behavioral /social science research tag; clinical research; ethanol; gamma aminobutyrate; genetically modified animals; human subject; human therapy evaluation; laboratory mouse; laboratory rat; naltrexone; receptor binding; receptor expression

This component describes plans for the support and management of a series of pilot projects, including procedures for scientific and technical review. Pilot studies in the UConn ARC have served as the basis for the development of programs of research that are integral to the Center, but which also extend beyond it through a variety of other funding mechanisms. During the current grant cycle, pilot studies have resulted in a total of 14 peer-review publications and have contributed to five successful grant applications, which have been funded through R01, R03, or R21 mechanisms. In these ways, the pilot studies program has played a crucial role in the vitality and growth of the UConn ARC. Seven separate projects are described, of which three will be initiated during the first two years of the grant period (Phase I). The remaining four projects are scheduled for implementation during the final three years of the grant (Phase II). Based upon the success of the pilot studies program during the current and previous grant periods, a tripartite approach is employed that focuses on three main investigational areas: neuropharmacology/neurobiology, electrophysiology/brain imaging, and treatment trials. This approach addresses the major research foci of the UConn ARC: vulnerability to alcohol-related problems; basic mechanisms of problem drinking, dependence, and relapse; and the treatment of alcohol dependence. During Phase I of the new grant period, proposed studies include the generation and phenotyping of transgenic mouse lines with altered expression of the GABAA receptor a6 subunit gene, a study of the electrophysiologic effects of hazardous drinking and depression in women, and a treatment trial that examines the safety and feasibility of using the opioid antagonist naltrexone to reduce problem drinking in adolescents. Studies to be conducted during Phase II of the grant cycle include a study of alcohol and neurosteroid modulation of GABA function and a study of the impact of purified antibodies directed against dopamine receptor subtypes on voluntary ethanol intake. This phase will also include a study of the effects of alcohol, cocaine, and antisocial personality disorder on cerebral blood flow, measured using functional MRI. Finally, Phase II will include a trial evaluating the effects of a low-cost, contingent reinforcement approach on ambulatory treatment attendance and retention, and on alcohol and drug use in alcohol-dependent patients.

该组件描述了支持和管理系列的计划 试点项目，包括科学和技术的程序 审查。 UConn Arc的试点研究已成为 开发与中心不可或缺的研究计划，但 这也通过各种其他资金机制超越了它。 在当前的赠款周期中，试点研究总共 14个同行评审出版物，并为五项成功的赠款做出了贡献 通过R01，R03或R21机制资助的应用。 通过这些方式，试点研究计划在 UCONN弧的活力和生长。 描述了七个单独的项目，其中将启动三个项目 在赠款期的前两年（第一阶段）。其余 计划在最后三个项目中计划实施四个项目 赠款年（第二阶段）。基于试点研究的成功 在当前和以前的赠款期间的计划，三方 采用了专注于三个主要研究领域的方法： 神经药理学/神经生物学，电生理学/脑成像和 治疗试验。这种方法探讨了主要研究重点 UCONN ARC：与酒精有关的问题的脆弱性；基本机制 饮酒，依赖和复发问题；和酒精的治疗 依赖。 在新赠款期的第一阶段，拟议的研究包括 转基因小鼠系的生成和表型随着变化 GABAA受体A6亚基基因的表达，一项研究 危险饮酒和抑郁症对女性的电生理效果， 以及检查使用的安全性和可行性的治疗试验 阿片类药物拮抗剂纳曲酮，以减少饮酒的问题 青少年。在赠款周期的第二阶段进行的研究 包括对GABA功能的酒精和神经类固醇调节的研究 并研究针对多巴胺的纯化抗体的影响 自愿乙醇摄入的受体亚型。这个阶段也将 包括对酒精，可卡因和反社会的影响的研究 使用功能测量的大脑血流的人格障碍 MRI。最后，第二阶段将包括评估A的影响 卧床治疗的低成本，应加固方法 出勤率和保留，以及依赖酒精的酒精和药物使用 患者。